نتایج جستجو برای: genomic targeted therapy

تعداد نتایج: 883589  

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006
Marta Cremonesi Mahila Ferrari Lisa Bodei Giampiero Tosi Giovanni Paganelli

The potential of targeted therapy with radiolabeled peptides has been reported in several clinical trials. Although there have been many improvements in dose estimation, a general and reliable dosimetric approach in peptide receptor radionuclide therapy (PRRT) is still a matter of debate. This article reviews the methods for PRRT dosimetry and the results presented in the literature. Radiopharm...

2015
Angela K.J. Park Joshua M. Francis Woong-Yang Park Joon-Oh Park Jeonghee Cho

Genomic alterations targeting the Epidermal Growth Factor Receptor (EGFR) gene have been strongly associated with cancer pathogenesis. The clinical effectiveness of EGFR targeted therapies, including small molecules directed against the kinase domain such as gefitinib, erlotinib and afatinib, have been proven successful in treating non-small cell lung cancer patients with tumors harboring EGFR ...

2015
Gro Vatne Røsland Agnete Svendsen Tenfjord Engelsen

New molecular insight reveals novel points of attack for targeted cancer therapy. The recent advances in cancer genomics and novel insight into the complex biology of cancer make the promise of personalized, targeted cancer medicine closer than ever. The massive parallel sequencing endeavours performed by The Cancer Genome Atlas, the International Cancer Genome Consortium and by numerous indivi...

2015
Doo-Yi Oh Seokhwi Kim Yoon-La Choi Young Jae Cho Ensel Oh Jung-Joo Choi Kyungsoo Jung Ji-Young Song Suzie E. Ahn Byoung-Gie Kim Duk-Soo Bae Woong-Yang Park Jeong-Won Lee Sangyong Song

Surgery and radiation are the current standard treatments for cervical cancer. However, there is no effective therapy for metastatic or recurrent cases, necessitating the identification of therapeutic targets. In order to create preclinical models for screening potential therapeutic targets, we established 14 patient-derived xenograft (PDX) models of cervical cancers using subrenal implantation...

2015
Alexander Drilon Lu Wang Maria E. Arcila Sohail Balasubramanian Joel R. Greenbowe Jeffrey S. Ross Phil Stephens Doron Lipson Vincent A. Miller Mark G. Kris Marc Ladanyi Naiyer A. Rizvi

Purpose: Broad, hybrid capture–based next-generation sequencing (NGS), as a clinical test, uses less tissue to identify more clinically relevant genomic alterations compared with profiling with multiple non-NGS tests. We set out to determine the frequency of such genomic alterations via this approach in tumors in which previous extensive non-NGS testing had not yielded a targetable driver alter...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
Alexander Drilon Lu Wang Maria E Arcila Sohail Balasubramanian Joel R Greenbowe Jeffrey S Ross Phil Stephens Doron Lipson Vincent A Miller Mark G Kris Marc Ladanyi Naiyer A Rizvi

PURPOSE Broad, hybrid capture-based next-generation sequencing (NGS), as a clinical test, uses less tissue to identify more clinically relevant genomic alterations compared with profiling with multiple non-NGS tests. We set out to determine the frequency of such genomic alterations via this approach in tumors in which previous extensive non-NGS testing had not yielded a targetable driver altera...

Journal: :Annals of Oncology 2022

Genomics has not yet been integrated into the clinical practice of Radiation Oncology. Liquid biopsy is a non-invasive tool based on study circulating tumor DNA (ctDNA), mainly applied to advanced cancer patients treated with chemotherapy. This work assesses utility liquid in early-stage/oligometastatic undergoing stereotactic body radiation therapy (SBRT). Next-generation sequencing (NGS) geno...

2017
Roman Groisberg David S. Hong Vijaykumar Holla Filip Janku Sarina Piha-Paul Vinod Ravi Robert Benjamin Shreyas Kumar Patel Neeta Somaiah Anthony Conley Siraj M. Ali Alexa B. Schrock Jeffrey S. Ross Philip J. Stephens Vincent A. Miller Shiraj Sen Cynthia Herzog Funda Meric-Bernstam Vivek Subbiah

BACKGROUND There are currently no United States Food and Drug Administration approved molecularly matched therapies for sarcomas except gastrointestinal stromal tumors. Complicating this is the extreme diversity, heterogeneity, and rarity of these neoplasms. Few therapeutic options exist for relapsed and refractory sarcomas. In clinical practice many oncologists refer patients for genomic profi...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید